James Ford - GSK Plc Senior Vice President General Counsel
| GLAXF Stock | USD 16.89 0.25 1.46% |
President
Mr. James Ford serves as Senior Vice President General Counsel of the Company. James joined the CET in 2018, when he was appointed Senior Vice President and General Counsel. He joined GSK in 1995 and has served as General Counsel Consumer Healthcare, General Counsel Global Pharmaceuticals, Vice President of Corporationrationrate Legal and Acting Head of Governance, Ethics and Compliance. Prior to GSK, James was a solicitor at Clifford Chance and DLA. He holds a law degree from University of East Anglia and a Diploma in Competition Law from Kings College. He is qualified as a solicitor in England and Wales, and is an attorney at the New York State Bar. since 2018.
| Tenure | 6 years |
| Phone | 44 20 8047 5000 |
| Web | https://www.gsk.com |
GSK Plc Management Efficiency
The company has return on total asset (ROA) of 0.0659 % which means that it generated a profit of $0.0659 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3131 %, meaning that it generated $0.3131 on every $100 dollars invested by stockholders. GSK Plc's management efficiency ratios could be used to measure how well GSK Plc manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Menelas Pangalos | AstraZeneca PLC ADR | 57 | |
| Sandra Leung | Bristol Myers Squibb | 60 | |
| Samit Hirawat | Bristol Myers Squibb | 52 | |
| David Fredrickson | AstraZeneca PLC ADR | N/A | |
| Patrick MD | Novartis AG ADR | 54 | |
| James Bradner | Novartis AG ADR | 49 | |
| Fiona Marshall | Novartis AG ADR | 60 | |
| Ruud Dobber | AstraZeneca PLC ADR | N/A | |
| Iskra Reic | AstraZeneca PLC ADR | N/A | |
| David Elkins | Bristol Myers Squibb | 56 | |
| JeanBaptiste Chatillon | Sanofi ADR | 59 | |
| Joseph Eid | Bristol Myers Squibb | 52 | |
| Shreeram MD | Novartis AG ADR | 61 | |
| Katarina Ageborg | AstraZeneca PLC ADR | N/A | |
| Adam Dubow | Bristol Myers Squibb | 53 | |
| Leon Wang | AstraZeneca PLC ADR | N/A | |
| Fiona Cicconi | AstraZeneca PLC ADR | N/A | |
| Ann Powell | Bristol Myers Squibb | 55 | |
| Susanne Schaffert | Novartis AG ADR | 54 | |
| MarieFrance Tschudin | Novartis AG ADR | 53 | |
| Jyoti Mehra | Gilead Sciences | 48 | |
Management Performance
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 |
GSK plc Leadership Team
Elected by the shareholders, the GSK Plc's board of directors comprises two types of representatives: GSK Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GSK. The board's role is to monitor GSK Plc's management team and ensure that shareholders' interests are well served. GSK Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GSK Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Redfern, Chief Strategy Officer | ||
| Diana Conrad, Chief Officer | ||
| Emma Walmsley, President - Consumer Healthcare Worldwide | ||
| Sally Jackson, VP Office | ||
| Iain Mackay, CFO - Designate, Executive Director | ||
| James Ford, Senior Vice President General Counsel | ||
| Shobie Ramakrishnan, Chief Officer | ||
| Sarah EltonFarr, Head Relations | ||
| Julie Brown, Chief Officer | ||
| Tony Wood, Chief Officer |
GSK Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is GSK Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 90.86 B | |||
| Shares Outstanding | 4.09 B | |||
| Shares Owned By Insiders | 0.60 % | |||
| Shares Owned By Institutions | 41.06 % | |||
| Price To Earning | 11.44 X | |||
| Price To Book | 6.49 X |
Currently Active Assets on Macroaxis
Other Information on Investing in GSK Pink Sheet
GSK Plc financial ratios help investors to determine whether GSK Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GSK with respect to the benefits of owning GSK Plc security.